Concomitant use of clopidogrel and proton pump inhibitors: A retrospective analysis of prescription behaviour.
- Published in:
- British Journal of Clinical Pharmacology, 2025, v. 91, n. 6, p. 1739, doi. 10.1111/bcp.16402
- By:
- Publication type:
- Article
Works matching DE "OMEPRAZOLE"
Results: 1853
1
2
Formulation Approaches for Optimizing Omeprazole Stability in Oral Liquid Dosage Forms.
- Published in:
- Pharmaceutics, 2025, v. 17, n. 5, p. 594, doi. 10.3390/pharmaceutics17050594
- By:
- Publication type:
- Article
3
A Novel Method for Pain Relief in Chronic Pancreatitis: an Old Drug in a New Pack: a Controlled Study.
- Published in:
- Indian Journal of Surgery, 2017, v. 79, n. 6, p. 549, doi. 10.1007/s12262-016-1526-6
- By:
- Publication type:
- Article
4
Sensitive amperometric detection of omeprazole and pantoperazole at electrodeposited nickel oxide nanoparticles modified glassy carbon electrode.
- Published in:
- Journal of Solid State Electrochemistry, 2012, v. 16, n. 4, p. 1369, doi. 10.1007/s10008-011-1536-z
- By:
- Publication type:
- Article
5
Pharmacotherapeutic actions related to drug interaction alerts – a questionnaire study among Swedish hospital interns and residents in family medicine.
- Published in:
- European Journal of Clinical Pharmacology, 2025, v. 81, n. 2, p. 301, doi. 10.1007/s00228-024-03785-4
- By:
- Publication type:
- Article
6
The benefit of omeprazole exposure on all-cause mortality and length of ICU/hospital stay might vary with age in critically ill pediatric patients: A cohort study.
- Published in:
- European Journal of Clinical Pharmacology, 2024, v. 80, n. 1, p. 115, doi. 10.1007/s00228-023-03588-z
- By:
- Publication type:
- Article
7
Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients.
- Published in:
- European Journal of Clinical Pharmacology, 2023, v. 79, n. 9, p. 1271, doi. 10.1007/s00228-023-03538-9
- By:
- Publication type:
- Article
8
Time-dependent association between omeprazole and esomeprazole and hospitalization due to hyponatremia.
- Published in:
- European Journal of Clinical Pharmacology, 2023, v. 79, n. 1, p. 71, doi. 10.1007/s00228-022-03423-x
- By:
- Publication type:
- Article
9
Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects.
- Published in:
- European Journal of Clinical Pharmacology, 2022, v. 78, n. 11, p. 1823, doi. 10.1007/s00228-022-03393-0
- By:
- Publication type:
- Article
10
Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans.
- Published in:
- European Journal of Clinical Pharmacology, 2022, v. 78, n. 6, p. 975, doi. 10.1007/s00228-022-03304-3
- By:
- Publication type:
- Article
11
Comparative analysis of PIM criteria and drug labels in the elderly.
- Published in:
- European Journal of Clinical Pharmacology, 2022, v. 78, n. 2, p. 197, doi. 10.1007/s00228-021-03262-2
- By:
- Publication type:
- Article
12
Effect of proton pump inhibitors on voriconazole concentrations in Chinese patients with malignant hematological diseases.
- Published in:
- European Journal of Clinical Pharmacology, 2020, v. 76, n. 6, p. 833, doi. 10.1007/s00228-020-02841-z
- By:
- Publication type:
- Article
13
Phenytoin intoxication associated with omeprazole administration in a child with defective CYP2C9.
- Published in:
- 2020
- By:
- Publication type:
- Letter
14
Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial.
- Published in:
- European Journal of Clinical Pharmacology, 2019, v. 75, n. 5, p. 639, doi. 10.1007/s00228-019-02625-0
- By:
- Publication type:
- Article
15
Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study.
- Published in:
- European Journal of Clinical Pharmacology, 2019, v. 75, n. 2, p. 237, doi. 10.1007/s00228-018-2569-3
- By:
- Publication type:
- Article
16
Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000-2016.
- Published in:
- European Journal of Clinical Pharmacology, 2019, v. 75, n. 2, p. 227, doi. 10.1007/s00228-018-2564-8
- By:
- Publication type:
- Article
17
Clinically relevant drug-drug interactions among elderly people with dementia.
- Published in:
- European Journal of Clinical Pharmacology, 2018, v. 74, n. 10, p. 1351, doi. 10.1007/s00228-018-2514-5
- By:
- Publication type:
- Article
18
Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer's disease.
- Published in:
- European Journal of Clinical Pharmacology, 2017, v. 73, n. 9, p. 1149, doi. 10.1007/s00228-017-2273-8
- By:
- Publication type:
- Article
19
Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions.
- Published in:
- European Journal of Clinical Pharmacology, 2017, v. 73, n. 7, p. 855, doi. 10.1007/s00228-017-2250-2
- By:
- Publication type:
- Article
20
Seizure and tetany secondary to hypomagnesaemic hypoparathyroidism induced by a proton-pump inhibitor.
- Published in:
- 2017
- By:
- Publication type:
- Letter
21
Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease.
- Published in:
- European Journal of Clinical Pharmacology, 2016, v. 72, n. 6, p. 711, doi. 10.1007/s00228-016-2033-1
- By:
- Publication type:
- Article
22
A limited sampling strategy based on maximum a posteriori Bayesian estimation for a five-probe phenotyping cocktail.
- Published in:
- European Journal of Clinical Pharmacology, 2016, v. 72, n. 1, p. 39, doi. 10.1007/s00228-015-1953-5
- By:
- Publication type:
- Article
23
Possible drug-drug interaction between high-dose esomeprazole and phenprocoumon.
- Published in:
- European Journal of Clinical Pharmacology, 2015, v. 71, n. 12, p. 1461, doi. 10.1007/s00228-015-1912-1
- By:
- Publication type:
- Article
24
Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients.
- Published in:
- European Journal of Clinical Pharmacology, 2015, v. 71, n. 9, p. 1059, doi. 10.1007/s00228-015-1882-3
- By:
- Publication type:
- Article
25
Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway.
- Published in:
- European Journal of Clinical Pharmacology, 2015, v. 71, n. 5, p. 617, doi. 10.1007/s00228-015-1834-y
- By:
- Publication type:
- Article
26
Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese.
- Published in:
- European Journal of Clinical Pharmacology, 2014, v. 70, n. 9, p. 1073, doi. 10.1007/s00228-014-1713-y
- By:
- Publication type:
- Article
27
Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.
- Published in:
- European Journal of Clinical Pharmacology, 2014, v. 70, n. 2, p. 167, doi. 10.1007/s00228-013-1603-8
- By:
- Publication type:
- Article
28
A cytochrome P450 phenotyping cocktail causing unexpected adverse reactions in female volunteers.
- Published in:
- European Journal of Clinical Pharmacology, 2013, v. 69, n. 12, p. 1997, doi. 10.1007/s00228-013-1561-1
- By:
- Publication type:
- Article
29
Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates.
- Published in:
- European Journal of Clinical Pharmacology, 2014, v. 70, n. 1, p. 37, doi. 10.1007/s00228-013-1592-7
- By:
- Publication type:
- Article
30
Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study.
- Published in:
- European Journal of Clinical Pharmacology, 2013, v. 69, n. 9, p. 1709, doi. 10.1007/s00228-013-1524-6
- By:
- Publication type:
- Article
31
The ( R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.
- Published in:
- European Journal of Clinical Pharmacology, 2013, v. 69, n. 7, p. 1423, doi. 10.1007/s00228-013-1480-1
- By:
- Publication type:
- Article
32
Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood.
- Published in:
- European Journal of Clinical Pharmacology, 2012, v. 68, n. 5, p. 629, doi. 10.1007/s00228-011-1151-z
- By:
- Publication type:
- Article
33
Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers.
- Published in:
- European Journal of Clinical Pharmacology, 2012, v. 68, n. 5, p. 553, doi. 10.1007/s00228-011-1174-5
- By:
- Publication type:
- Article
34
Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.
- Published in:
- European Journal of Clinical Pharmacology, 2012, v. 68, n. 4, p. 407, doi. 10.1007/s00228-011-1136-y
- By:
- Publication type:
- Article
35
CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking.
- Published in:
- European Journal of Clinical Pharmacology, 2010, v. 66, n. 9, p. 871, doi. 10.1007/s00228-010-0835-0
- By:
- Publication type:
- Article
36
Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers.
- Published in:
- European Journal of Clinical Pharmacology, 2010, v. 66, n. 6, p. 563, doi. 10.1007/s00228-010-0821-6
- By:
- Publication type:
- Article
37
Pharmacokinetics of intravenous omeprazole in critically ill paediatric patients.
- Published in:
- European Journal of Clinical Pharmacology, 2010, v. 66, n. 4, p. 323, doi. 10.1007/s00228-009-0774-9
- By:
- Publication type:
- Article
38
Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes.
- Published in:
- European Journal of Clinical Pharmacology, 2009, v. 65, n. 6, p. 601, doi. 10.1007/s00228-008-0608-1
- By:
- Publication type:
- Article
39
The bioavailability of bromazepam, omeprazole and paracetamol given by nasogastric feeding tube.
- Published in:
- European Journal of Clinical Pharmacology, 2009, v. 65, n. 5, p. 435, doi. 10.1007/s00228-008-0613-4
- By:
- Publication type:
- Article
40
Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH.
- Published in:
- European Journal of Clinical Pharmacology, 2009, v. 65, n. 1, p. 19, doi. 10.1007/s00228-008-0576-5
- By:
- Publication type:
- Article
41
Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects.
- Published in:
- European Journal of Clinical Pharmacology, 2008, v. 64, n. 12, p. 1175, doi. 10.1007/s00228-008-0529-z
- By:
- Publication type:
- Article
42
Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers.
- Published in:
- European Journal of Clinical Pharmacology, 2008, v. 64, n. 9, p. 901, doi. 10.1007/s00228-008-0510-x
- By:
- Publication type:
- Article
43
Effects of the CYP3A5 genotype on omeprazole sulfoxidation in CYP2C19 PMs.
- Published in:
- European Journal of Clinical Pharmacology, 2008, v. 64, n. 6, p. 583, doi. 10.1007/s00228-008-0461-2
- By:
- Publication type:
- Article
44
Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration.
- Published in:
- European Journal of Clinical Pharmacology, 2007, v. 63, n. 11, p. 1031, doi. 10.1007/s00228-007-0331-3
- By:
- Publication type:
- Article
45
Absolute bioavailability and metabolism of omeprazole in relation to CYP2C19 genotypes following single intravenous and oral administrations.
- Published in:
- European Journal of Clinical Pharmacology, 2007, v. 63, n. 2, p. 143, doi. 10.1007/s00228-006-0251-7
- By:
- Publication type:
- Article
46
Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese.
- Published in:
- European Journal of Clinical Pharmacology, 2006, v. 62, n. 11, p. 939, doi. 10.1007/s00228-006-0189-9
- By:
- Publication type:
- Article
47
Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4.
- Published in:
- European Journal of Clinical Pharmacology, 2006, v. 62, n. 8, p. 621, doi. 10.1007/s00228-006-0156-5
- By:
- Publication type:
- Article
48
Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo.
- Published in:
- European Journal of Clinical Pharmacology, 2006, v. 62, n. 7, p. 539, doi. 10.1007/s00228-006-0121-3
- By:
- Publication type:
- Article
49
Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?
- Published in:
- European Journal of Clinical Pharmacology, 2006, v. 62, n. 6, p. 473, doi. 10.1007/s00228-006-0131-1
- By:
- Publication type:
- Article
50
Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
- Published in:
- European Journal of Clinical Pharmacology, 2006, v. 62, n. 2, p. 107, doi. 10.1007/s00228-005-0063-1
- By:
- Publication type:
- Article